All News

Benyam Muluneh, PharmD, BCOP, CPP, assistant professor at the University of North Carolina Eshelman School of Pharmacy, discusses his presentation at the HOPA 2022 annual conference on the Oral Chemotherapy Collaborative (OCC) and how it works to optimize care for patients taking oral anti-cancer agents.

Cabotegravir is the only current HIV-1 PrEP medication that does need to be taken daily.

The companies plan to submit these data to the FDA in the coming days for an Emergency Use Authorization of a booster dose for children ages 5 through 11 in the United States.

Vusolimogene oderparepvec is in development for the treatment of multiple skin cancers either alone or in combination with anti-PD1 therapy.

Patient’s lawsuit alleges 4 legal theories as bases for liability, including defamation and emotional distress.

On this week's episode, Suzy welcomes 2021 Women Pharmacist of the Year winners to celebrate their work and discuss key trends in pharmacy.

Because there is an inflammatory component to Down syndrome regression disorder, it may potentially be reversible with immunotherapy.

Ponesimod (Ponvory) is indicated for the treatment of relapsing forms of multiple sclerosis.

Bismuth subsalicylate is indicated for heartburn, indigestion, and upset stomach.

The investigational selective, covalent, and orally bioavailable KRASG12C¬ inhibitor shows a 57% confirmed overall response rate at the recommended dose of 200 mg twice daily.

Pharmacists should review the medications of patients with multiple sclerosis regularly to assess drug-drug interactions.

The FDA previously granted Fast Track Designation for the combination of lifileucel and pembrolizumab in metastatic melanoma.

Relevant training and credentials lead to technicians taking a more active role in pharmacies.

Based on event-free survival and pathologic complete response results, the FDA approved nivolumab in combination with platinum-doublet chemotherapy in March 2022.

Results are from an exploratory analysis of 34 patients who received at least 1 dose after disease progression or suboptimal response with ruxolitinib monotherapy

Here are 8 diabetes areas where pharmacists should be more aware of error.

Results show that 64% of individuals treated with lorlatinib were without disease progression after 3 years compared with about 19% of those treated with crizotinib (Xalkori).

Brimonidine tartrate/timolol maleate ophthalmic solution 0.2%/0.5% is a generic equivalent to AbbVie’s Combigan, which reduces eye pressure in patients with ocular hypertension.

Numbers have remained below prepandemic levels.

V116 is a novel 21-valent pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease and pneumococcal pneumonia.

Blue Earth Therapeutics will begin an open-label, multicenter trial to evaluate a next-generation radiopharmaceutical for metastatic castration-resistant prostate cancer.

Abrocitinib (Cibinqo) is a Janus kinase inhibitor indicated for the treatment of adults with refractory moderate-to-severe atopic dermatitis.

Culturelle Probiotics Kids supports immune and digestive health.

Investigators focus on understanding the difference in the microenvironments that surround cancer cells in the primary tumor versus the sites where it metastasizes.

It is imperative for health care professionals, especially pharmacists, to be well-informed regarding the physiological impact of Ramadan on diabetes.

Clinical data from phase 1/2 LIBRETTO trial show evidence of meaningful clinical outcomes for patients, including those with difficult-to-treat brain metastases.

Sotorasib demonstrates clinical benefit and prolonged tumor response seen, with a 40.7% objective response rate.

Analysis indicates that factors associated with psychological flourishing include being married and physically active, as well as free from chronic pain and anxiety and depression.

Entrepreneurism is actually more a function of hard work, networking, and certainly a dash of creative thinking than it is eccentricity, luck, or superior genius.

Ravulizumab-cwvz (Ultomiris) produced statistically significant improvements in measures of functional activity, muscle strength, and quality of life in patients with anti-acetylcholine receptor antibody-positive generalized myasthenia gravis.